TOMS RIVER, NJ — The Toms River Police Department is urgently requesting public assistance to locate Elaine Dicataldo, an Alzheimer’s patient who went missing earlier today. Elaine drove away from …
Alzheimer’s
-
-
(Reuters) – Biogen Inc said on Wednesday it would terminate a post-approval study of its first Alzheimer’s drug, Aduhelm, and discontinue all commercialization for the controversial treatment. The strategic shift …
-
By Julie Steenhuysen CHICAGO (Reuters) – Breakthrough Alzheimer’s treatments that remove toxic proteins from the brain have revived interest in vaccines to treat the memory-robbing disease, potentially offering a cheaper, …
-
By Deena Beasley (Reuters) – Blood tests for Alzheimer’s are needed to more widely diagnose the brain-wasting disease and understand its prevalence, but it will be another couple of years …
-
By Julie Steenhuysen CHICAGO (Reuters) – When Lianor da Cunha Hillerstrom of Lexington, Massachusetts, learned her now 9-year-old son Oskar had Down syndrome, she was concerned but not panicked. As …
-
NEWARK, NJ – Newark Public Safety Director Fritz G. Fragé has issued an urgent appeal to the public for assistance in locating 70-year-old Errol Bryan, who was reported missing on …
-
By Julie Steenhuysen and Deena Beasley CHICAGO (Reuters) – Five major U.S. health systems said they would offer Eisai and Biogen’s promising new Alzheimer’s drug Leqembi after working out payment …
-
(Reuters) – Eisai Co Ltd and Biogen Inc’s Leqembi emerged as the first Alzheimer’s treatment to win the U.S. Food and Drug Administration’s standard approval on Thursday, a milestone in …
-
By Deena Beasley The U.S. Food and Drug Administration on Thursday granted standard approval to Eisai and Biogen’s Leqembi for patients with Alzheimer’s disease. The FDA decision is expected to …
-
By Julie Steenhuysen CHICAGO (Reuters) -The U.S. Medicare health plan on Thursday offered details of plans to collect patient data as a condition for reimbursement for Eisai Co Ltd and …
-
By Natalie Grover LONDON (Reuters) – Diabetes drugs that also promote weight loss such as Novo Nordisk’s Ozempic, becoming a darling of celebrities and investors, are being studied to tackle …
-
By Deena Beasley and Julie Steenhuysen (Reuters) – Eli Lilly and Co expects the U.S. Medicare health plan to back down from strict coverage limits on new Alzheimer’s drugs as …
-
JAMES CARTER AND JAMES PINKERTON: There’s A Major Obstacle To Finding The Cure For Alzheimer’s James Carter And James Pinkerton on March 4, 2023 Three years ago, one of us …
-
(Reuters) – The $26,500-per-year price tag for Eisai Co Ltd and Biogen Inc’s newly approved Alzheimer’s disease drug is slightly above expectations, but should not dent demand for the promising …
-
(Reuters) – Japanese drugmaker Eisai Co Ltd said on Saturday it had submitted an application to the U.S. Food and Drug Administration for a standard review of its Alzheimer’s drug …
-
(Reuters) – The U.S. Food and Drug Administration on Friday approved Eisai Co Ltd and Biogen Inc’s Alzheimer’s drug lecanemab for the treatment of early forms of the fatal, brain-wasting …
-
By Julie Steenhuysen CHICAGO (Reuters) – Swiss drugmaker Roche is closing down most clinical trials of its experimental Alzheimer’s drug gantenerumab after it failed to slow advance of the mind-robbing …
-
By Deena Beasley and Julie Steenhuysen SAN FRANCISCO (Reuters) – Japan’s Eisai Co plans to seek full approval of its experimental Alzheimer’s drug lecanemab in the United States, Europe and …
-
By Julie Steenhuysen CHICAGO (Reuters) -The first big breakthrough in 30 years of Alzheimer’s research is providing momentum for clinical trials of “cocktail” treatments targeting the two hallmark proteins associated …
-
By Newark PD, Newark Public Safety Director Fritz G. Fragé seeks the public’s help in locating Rafael Rivera, 73, who was reported missing today, Friday, November 4, 2022. Mr. Rivera, …
-
By Julie Steenhuysen CHICAGO (Reuters) – Clear evidence this week that Eisai and Biogen’s drug lecanemab slows cognitive decline in early stage dementia has galvanized efforts among Alzheimer’s researchers toward …
-
NEWARK, NJ – Police in Newark have issued a silver alert for a missing 83-year-old man named Felix Perez, who went missing earlier in the day. “Mr. Perez, who suffers …
-
(Reuters) – Biogen said on Tuesday its Chief Executive Michel Vounatsos will step down, with the drugmaker adding it would scale down its sales infrastructure for the controversial Alzheimer’s drug …
-
By Deena Beasley – Patient groups are mounting a public pressure campaign aimed at persuading the U.S. government to loosen proposed restrictions on new Alzheimer’s treatments, spending millions of dollars …
-
Biogen, and its Japanese partner Eisai, announced Monday that it plans to begin the process for U.S. approval for its experimental drug for Alzheimer’s. Biogen and Eisai announced “rolling submission” …